Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient

Nivolumab, an anti-PD-1 check point inhibitor, is an immunotherapeutic agent, representing a major step in the treatment of melanoma. However, its use is associated with severe toxicities. Among them, gastrointestinal (GI) disorders from the lower GI tract have been widely reported. On the contrary,...

Descripción completa

Detalles Bibliográficos
Autores principales: Samonis, George, Bousmpoukea, Aikaterini, Molfeta, Aristea, Kalkinis, Antonios D., Petraki, Kalliopi, Koutserimpas, Christos, Bafaloukos, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689097/
https://www.ncbi.nlm.nih.gov/pubmed/36428923
http://dx.doi.org/10.3390/diagnostics12112864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689097/
https://www.ncbi.nlm.nih.gov/pubmed/36428923
http://dx.doi.org/10.3390/diagnostics12112864

Ejemplares similares